Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025

4. Boston Scientific Corporation (NYSE:BSX)

Millennium Management’s Stake Value: $910.05 Million

Number of Hedge Fund Holders: 92

Boston Scientific Corporation (NYSE:BSX) is a healthcare company that develops, manufactures, and markets medical devices worldwide for use in various interventional medical specialties. It offers devices to diagnose and treat gastrointestinal and pulmonary conditions. The stock was up by about 56% in 2024, benefiting from impressive financial results that affirmed underlying growth.

Boston Scientific Corporation (NYSE:BSX) released better-than-expected third-quarter revenue and earnings at the end of October. Cardiovascular sales increased 25% to $2.73 billion, while total sales grew 18.2% organically. Boston Scientific’s other division, medical-surgical sales, generated $1.48 billion in revenue, an increase of 10.3%.

In contrast to its previous guidance of $2.38 to $2.42 per share, Boston Scientific increased its profit outlook for the year to an adjusted $2.45 to $2.47 per share, affirming expected growth. Additionally, Boston Scientific anticipates organic full-year sales growth of roughly 15%, which is higher than its prior range of 13% to 14% growth.

The impressive financial results and guidance are fueled by strong performance from key products like Farapulse. The products continue to capture market share from competing radiofrequency (RF) and cryoablation technologies. Additionally, Boston Scientific Corporation (NYSE:BSX) has moved to strengthen its prospects in sacral neuromodulation (SNM), a high-growth adjacency for its Urology business.

It has also completed the acquisition of Axonics, a medical technology company focused on developing and commercializing differentiated devices to treat urinary and bowel dysfunction. The acquisition is strategic, strengthening the company’s ability to offer clinically differentiated treatment options with well-established therapies in a high-growth adjacency.